GlassScriptPhysician profile
Amber C Fowler
NPI 1780814327
$2,479.18
in general payments reported to CMS, 2019-2025
28 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $544 · 2022: $999 · 2023: $370 · 2024: $256 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $476.16 | 2021-2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $426.78 | 2022-2025 | Airsupra |
| Philips North America LLC | $204.37 | 2022 | |
| Glaxosmithkline, LLC. | $176.63 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| United Therapeutics Corporation | $172.33 | 2021-2023 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $109.03 | 2021-2023 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $93.74 | 2022-2023 | |
| Genzyme Corporation | $93.53 | 2021-2023 | |
| Inspire Medical Systems, INC. | $93.15 | 2023-2025 | Inspire |
| Mylan Specialty L.P. | $79.08 | 2021-2023 | Yupelri |
| Abiomed | $76.57 | 2025 | |
| Amgen INC. | $54.51 | 2022 | |
| Insmed, INC. | $43.03 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $41.80 | 2023 | Dupixent |
| Ambu INC. | $38.98 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.65 | 2022 | |
| Becton, Dickinson and Company | $32.49 | 2024 | Hemosphere |
| Resmed Corp | $28.48 | 2024-2025 | |
| Genentech USA, INC. | $27.49 | 2023 | Esbriet, Xolair |
| Gilead Sciences, INC. | $25.18 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.54 | 2021 | |
| Vapotherm INC | $20.34 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.12 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.94 | 2022 | |
| La Jolla Pharmaceutical Company | $18.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.13 | 2022 | |
| Pharming Healthcare, INC. | $16.38 | 2023 | Ruconest |
| Advanced Respiratory, INC | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.